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Abstract
Whereas the accumulation of fibroblasts and macrophages in breast cancer is a well-documented phenomenon and
correlates with metastatic disease, the functional contributions of these stromal cells on breast cancer progression
still remain largely unclear. Previous studies have uncovered a potentially important role for CCL2 inflammatory
chemokine signaling in regulatingmetastatic disease through amacrophage-dependentmechanism. In these studies,
we demonstrate a significant regulatory mechanism for CCL2 expression in fibroblasts in mediating mammary tumor
progression and characterize multiple functions for CCL2 in regulating stromal-epithelial interactions. Targeted abla-
tion of the transforming growth factor-β (TGF-β) type 2 receptor in fibroblasts (Tgfbr2FspKO) results in a high level of
secretion of CCL2, and cografts of Tgfbr2FspKO fibroblasts with 4T1 mammary carcinoma cells enhanced tumor pro-
gression associated with recruitment of tumor-associated macrophages (TAMs). Antibody neutralization of CCL2
in tumor-bearing mice inhibits primary tumor growth and liver metastases as evidenced by reduced cell proliferation,
survival, and TAM recruitment. Both high and low stable expressions of small interfering RNA to CCL2 in Tgfbr2FspKO
fibroblasts significantly reduce liver metastaseswithout significantly affecting primary tumor growth, cell proliferation,
or TAM recruitment. High but not low knockdownof CCL2 enhances tumor cell apoptosis. These data indicate that CCL2
enhances primary tumor growth, survival, and metastases in a dose-dependent manner, through TAM-dependent and
-independent mechanisms, with important implications on the potential effects of targeting CCL2 chemokine signaling
in the metastatic disease.
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Introduction
The induction of host inflammatory responses toward breast cancer
is characterized by the recruitment of stromal cells to the primary
tumor, including macrophages and fibroblasts [1,2]. Accumulation of
these stromal cells is associated with an increased expression of soluble
factors, which alters the tumor microenvironment including extracel-
lular matrix proteins, growth regulators, cytokines, and angiogenic fac-
tors, correlating with invasive breast cancer and poor patient prognosis
[3,4]. Whereas the accumulation of fibroblasts and macrophages in
breast cancer are a well-documented phenomenon, the signals that regu-
late the interplay between stromal and epithelial cancer cells remain
complex and largely unclear.
Abbreviations: siRNA, small interfering RNA; TAM, tumor-associated macrophage;
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A number of studies have indicated an important role for transform-
ing growth factor-β (TGF-β) signaling in regulating fibroblast activa-
tion. TGF-β signaling activates mammary fibroblasts by inhibiting
cell proliferation and inducing production of growth factors, angiogenic
factors, extracellular matrix proteins, and proteases [5,6]. Whereas the
role of autocrine TGF-β signaling in regulating themesenchymal pheno-
type has been well documented [6,7], recent reports have indicated a
significant role for TGF-β signaling in regulating interactions between
stromal and epithelial cells. In recent studies, the role of TGF-β sig-
naling in fibroblasts was analyzed by disrupting the expression of the
TGF-β type 2 receptor (Tgfbr2) in a subset of fibroblasts by Cre-Lox
(Tgfbr2FspKO). Cotransplanting mammary Tgfbr2FspKO fibroblasts with
PyVmT or 4T1 mammary carcinoma cells significantly enhanced pri-
mary tumor growth and progression [8,9]. Whereas the protumorigenic
phenotypes observed were associated with increased receptor tyrosine
kinase signaling, including the hepatocyte growth factor/c-Met signal-
ing pathway, abrogation of receptor tyrosine kinase signaling pathways
did not completely inhibit tumor progression enhanced by the TGF-β
signaling-deficient fibroblasts [8,9], indicating that TGF-β signaling
regulates stromal-epithelial interactions through mechanisms indepen-
dent of receptor tyrosine kinases.
The CCL2/CCR2 inflammatory chemokine signaling pathway has
been shown to be important in regulating macrophage recruitment
during inflammation and wound healing events [10,11]. Recent studies
have demonstrated a potentially important role for CCL2 in regulating
breast cancer progression in part through the recruitment of tumor-
associated macrophages (TAMs). A high level of CCL2 expression in
primary breast tumor has been shown to correlate with breast cancer
invasiveness and decreased patient survival [12,13]. In mouse studies,
a high level of expression of CCL2 in primary mammary tumors has
also been associated with high levels of TAMs, cells that lack immuno-
stimulatory function and secrete growth, survival, and angiogenic fac-
tors [14,15]. Tumor cells overexpressing recombinant CCL2 have
been shown to recruit TAMs that enhance tumor growth and meta-
static spread in mouse xenograft models of cancer [16,17], further
implicating CCL2 in a protumorigenic role in breast cancer through a
TAM-dependent mechanism.
This report shows that CCL2 and TGF-β signaling interacts to regu-
late stromal-epithelial interactions during mammary tumor progres-
sion. In these studies, Tgfbr2FspKO fibroblasts cografted with mammary
carcinoma cells enhanced primary tumor growth and liver metastases
statistically correlating with the accumulation of TAMs and increased ex-
pression of CCL2 in Tgfbr2FspKO fibroblasts. Antibody neutralization of
CCL2 in tumor-bearing mice inhibited tumor growth and metastatic
spread to the liver associated with reduced numbers of TAMs. Knock-
down of CCL2 by stable small interfering RNA (siRNA) expression in
Tgfbr2FspKO fibroblasts did not significantly affect primary tumor growth
but did significantly reduce liver metastases and moderately reduce TAM
recruitment. These data indicate that, whereas CCL2 in the breast cancer
microenvironment functions to enhance primary tumor growth, sur-
vival, and metastases in part through TAM recruitment, CCL2 derived
from mammary fibroblasts specifically functions to stimulate mammary
carcinoma cells to promote cell survival and metastatic spread. In sum-
mary, these data are the first to demonstrate that TGF-β signaling in
fibroblasts regulates metastatic disease through the CCL2 chemokine
signaling pathway. Furthermore, these studies demonstrate a fibroblast-
specific contribution of CCL2 to mammary tumor progression and are
the first to demonstrate dose-dependent effects of CCL2 on primary
tumor progression and TAM recruitment, with important implications
on the potential effects of targeting CCL2 inflammatory chemokines sig-
naling in metastatic disease.
Materials and Methods
Culture of Cell Lines
Floxed TGF-β type 2 receptor (Tgfbr2) control fibroblasts and
Tgfbr2fspKO fibroblasts were immortalized and characterized in previous
studies [8]. Fibroblasts, including stably expressingCCL2 siRNAcell lines,
were cultured inDulbecco’s modified Eaglemedium (DMEM)/F12/10%
fetal bovine serum (FBS). 4T1mammary carcinoma cells (American Type
Culture Collection, Manassas, VA) were cultured in DMEM/10 % FBS.
Phoenix cells were kindly provided by Jin Chen, MD, PhD, (Vanderbilt
University, Nashville, TN) and were cultured in DMEM/10% FBS.
siRNA Silencing of CCL2 Expression in
Tg fbr2FspKO Fibroblasts
The siRNA construct to target c-Met was obtained from Dr Martin
Schwartz (University of Virginia, Charlottesville, VA). TheH1 promoter
and targeting sequences were digested from the previously mentioned
constructs with HindIII and EcoRI and were cloned into the same sites
of an siRNA expression vector (pSUPER) or an siRNA retroviral vector
(pRETRO-SUPER). The pRETRO-SUPER vector was generously pro-
vided by Dr Reuven Agami (Division of Tumor Biology, The Nether-
lands Cancer Institute, Amsterdam, the Netherlands) and described in
Brummelkamp et al. [18]. The two targeting sequences used for siRNA-
mediated knockdown ofCCL2 are 5′-CAGAACCTACAACTTTATT-3′
for 1CCL2− and 5′-TAAATCTGAAGCTAATGCA-3′ for 3CCL2−.
The targeting sequence to silence enhanced GFP (eGFP) as a negative
control is 5′-GCTGACCCTGAAGTTCATC-3′. 1CCL2−, 3CCL2−,
and eGFP targeting oligonucleotides were designed as previously described
[18]. The oligonucleotides were phosphorylated by kinase treatment;
complementary oligos were then annealed and subcloned into the BglII
and HindIII sites of pRETRO-SUPER. Plasmids were transfected into
Phoenix cells by Lipofectamine 2000 (Invitrogen, Carlsbad, CA). Forty-
eight hours after transfection, Tgfbr2FspKO fibroblasts were transduced
with virus-conditioned medium and selected with 1.5 μg/ml puromycin.
Mouse Strains and Maintenance
Female nude (nu/nu) mice (6-8 weeks of age) were obtained from
Harlan Laboratories (Denver, CO). The experimental research on ro-
dents reported here has been performed with the approval of the ap-
propriate ethics committees, including the Association for Assessment
and Accreditation of Laboratory Animal Care and University of Kansas
Institutional Animal Care and Use Committee.
Subrenal Capsule Grafting
Grafting of collagen-embedded cells was performed according to
the methods of Hayward et al. [19]. Briefly, 1 × 105 4T1 cells were re-
suspended together with 2.5 × 105 Tgfbr2FspKO or Tgfbr2Flox/Flox fibro-
blasts in 50 μl of collagen per graft. The collagen-embedded cells were
cultured in DMEM/F12 10% FBS for 24 hours and then implanted
under the renal capsule layer of the kidneys in female nude mice, 6 to
8 weeks of age. Neutralizing antibodies that recognize murine-specific
CCL2 (R&D Systems,Minneapolis, MN) or control immunoglobulin G
(IgG; Sigma, St Louis, MO) were solubilized in 0.9% saline and injected
into the intraperitoneum into mice 7 days after grafting at 5 mg/kg, every
2 days for 14 days. Tumor tissues were collected 21 days after implan-
tation and weighed. Liver metastases were counted by examination of
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gross tissues. Metastatic lesions on the liver were confirmed by hema-
toxylin and eosin stain as previously shown [9].
Histology and Immunohistochemistry
Tumor tissues were fixed in 10% neutral formalin buffer, subjected to
dehydration in 50%, 70%, 80%, 95%, and 100% ethanols and xylene
and then paraffin-embedded. Five-micrometer sections were prepared
for immunohistochemistry. The sections were stained with hematoxylin
and eosin. Immunofluorescence staining of F4/80 (rat monoclonal; Ab-
cam, Cambridge, MA) was performed by 10 nM sodium citrate antigen
retrieval for 10 minutes at 105°C and by incubating primary antibodies
at a 1:50 dilution overnight at 4°C. Sections were incubated with rat
biotinylated secondary antibodies at a 1:500 dilution, conjugated to
streptavidin–Alexa 568 (1:500; Molecular Probes, Invitrogen, Carlsbad,
CA) and counterstained with 4′6′-diamidino-2-phenylindole. Sections
were mounted with Prolong Antifade (Molecular Probes). Immunoper-
oxidase staining for cleaved caspase-3 (rabbit polyclonal; Cell Signaling
Technologies, Boston, MA) and Ki67 (rabbit polyclonal; Dako, Carpin-
teria, CA) was performed by citrate antigen retrieval and by incubating
primary antibodies at a 1:100 dilution overnight at 4°C. Sections were
incubated with appropriate secondary biotinylated antibodies at a
1:500 dilution and conjugated to streptavidin peroxidase (Vectastain
Elite Kit; Vector Laboratories, Burlingame, CA) according to a commer-
cial protocol. Sections were visualized by peroxidase staining (Vectastain
Elite Kit; Vector Laboratories) and counterstainedwith hematoxylin. Pro-
liferative and apoptotic indices were calculated by determining the rela-
tive area of positively stained cells to the total number of cells in at least
five high-powered fields using Scion Image software (Frederick, MA).
Flow Cytometry Analysis
Primary tumor tissues were digested into single-cell suspensions
according to previously described studies [20]. Briefly, tumor tissues
were digested in PBS buffer containing 0.4 mg/ml collagenase, 2 mg/ml
Figure 1. Tgfbr2FspKO fibroblasts enhance recruitment of TAMs. (A) Primary tumor grafts were stained by immunofluorescence for F4/80
expression to detect TAMs. Sections were counterstained with DAPI. Arrows point to F4/80-positive cells. Scale bar, 40 μm. (B) Flow cy-
tometry analysis of primary tumor digests for F4/80, Cd11b-positive cells from 4T1 cells cografted with control Tgfbr2Flox/Flox (n = 10) or
Tgfbr2FspKO fibroblasts (n=10). Values are depicted asmean± SEM. *Statistical significance was determined by two-tailed Student’s t test,
P< .05 in comparison to 4T1:Tgfbr2Flox/Flox controls. Statistical significance was determined by P< .05. Spearman rank correlation analysis
of primary tumormasses (C) and number of livermetastases (D) with F4/80, Cd11b-positive cell recruitment to the primary tumor of 4T1 cells
grafted with Tgfbr2FspKO fibroblasts. Statistical significance was determined by P < .05.
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hyaluronidase, and 2mg/ml trypsin and separated into a single-cell suspen-
sion using a manual tissue homogenizer. Debris were removed by passing
through a mesh filter, and red blood cells were lysed using a buffer con-
taining 10 mM KHCO3, 150 mM NH4Cl, and 0.1 mM EDTA. Sam-
ples were incubated with anti–F4/80-PE (AbdSerotec, Oxford, UK),
anti–Cd11b-FITC, and anti–Gr1-APC (BD Pharmingen, San Jose,
CA), 1:100 on ice, washedwith PBS, and then analyzed by flow cytometry
using a BD FACS analyzer (BD Biosciences, San Jose, CA).
Determination of CCL2 Levels in Fibroblasts
To determine the levels of CCL2 secreted from fibroblasts in culture by
ELISA, immortalized and primary cultures of fibroblasts from Tgfbr2Flox/
Flox and Tgfbr2fspKO mammary glands were grown in 10-cm plates in
DMEM/F12medium containing 10% FBS and antibiotics. At 80% con-
fluence, the cells were starved in DMEM F12 medium containing 0.1%
FBS for 24 hours and were then incubated in 4 ml of complete medium
for another 24 hours. Levels of secreted CCL2 protein were determined
by ELISA (R&D Systems) using 100 μl of conditioned medium. Statisti-
cal significance was determined by two-tailed Student’s t test.
Determination of Anti-CCL2 and IgG Levels in
Tumor-Bearing Mice
To determine the levels of anti-CCL2 and control IgG in tumor-
bearing mice by ELISA, blood sera were collected from the tail vein of
grafted mice 4 and 24 hours after the last treatment with anti-CCL2
or IgG. The samples were then diluted in buffer containing 50 mM
NaHCO3 and 50mMNa2CO3, pH 9.6, and coated onto 96-well plates
overnight at room temperature. The samples were incubated with anti-
rat biotinylated antibodies (1:500) for 1 hour and then with streptavidin
peroxidase (Vectastain Elite Kit; Vector Laboratories) for an additional
30minutes. The samples were visualized by incubatingwith tetramethyl-
benzidine substrate (R&D Systems) according to the manufacturer’s in-
structions. The reaction was stopped with 1MHCl, and the absorbance
was read at OD 450 nm.
Statistical Analyses
Data were analyzed for statistical significance by two-tailed Student’s
t test, ANOVAwith Bonferroni’s multiple comparison tests of all groups,
or Spearman rank correlation test as indicated, using GraphPad Prism
software (GraphPad Software, La Jolla, CA). Statistical significance was
determined by P < 0.05.
Results
Tg fbr2FspKO Fibroblasts Enhance Recruitment of TAMs to the
Primary Tumor Associated with Increased Expression of CCL2
In previous studies, Tgfbr2-deficient fibroblasts cografted with mam-
mary carcinoma cells [8,9] resulted in enhanced primary tumor growth
Figure 2. Increased expression of CCL2 in Tgfbr2FspKO stromal cells. (A) Secretion of CCL2 from fibroblast conditionedmedium from primary
and immortalized Tgfbr2Flox/Flox and Tgfbr2FspKO fibroblasts was quantified by ELISA. Statistical significance was determined by two-tailed
Student’s t test. Statistical significance was determined by P< .05, in comparison to Flox/Flox controls. (B) Immunohistochemistry staining of
CCL2 in the stroma of primary tumor subrenal grafts. s indicates stroma; t, tumor. Scale bar, 40 μm (a, c, e). Scale bar, 20 μm (b, d, f).
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and invasiveness and metastatic spread. Studies have shown that ac-
cumulation of immune cells, in particular, TAMs, correlates with the
invasive phenotype of breast cancers; therefore, it was important to
determine whether Tgfbr2-deficient fibroblasts significantly affected
recruitment of macrophages to the primary tumor. Tgfbr2FspKO fibro-
blasts were cografted with 4T1 mammary carcinoma cells in the sub-
renal capsule of nude mice for 21 days and subjected to flow cytometry
analysis for a number of cells coexpressing F4/80 and Cd11b, markers
associated with TAMs [14]. Tgfbr2FspKO fibroblasts cografted with
4T1 mammary carcinoma cells resulted in significantly higher levels
of F4/80, Cd11b double-positive macrophages compared with mam-
mary carcinoma cells cografted with control Tgfbr2Flox/Flox fibroblasts
(Figure 1, A and B). Furthermore, correlation analyses revealed a sig-
nificant association between the increased numbers of F4/80, Cd11b-
positive cells recruited to the primary tumor, with the increased primary
tumor growth and liver metastases of mammary carcinoma cells co-
grafted with Tgfbr2FspKO fibroblasts (Figure 1, C and D).
Previous studies have shown that macrophage recruitment in part is
regulated by the expression of chemokines in the tissue microenviron-
ment [16,21]. In particular, CCL2 was previously shown a significant
regulator of macrophage recruitment during inflammation and tumori-
genesis [1,22]. By Affymetrix complementary DNA microarray analy-
sis, CCL2 was observed to be the most significantly upregulated of all
chemokines in Tgfbr2FspKO fibroblasts, in comparison with control
fibroblasts (data not shown). This upregulated expressionwas confirmed
by ELISA of supernatants isolated from cultured primary and immor-
talized Tgfbr2FspKO and control Tgfbr2Flox/Flox fibroblasts (Figure 2A).
Furthermore, primary tumors cografted with Tgfbr2FspKO fibroblasts
also showed high levels of CCL2 expression localized to the stromal
fibroblast compartment, which was absent in the stromal tissues of
primary tumors cografted with control fibroblasts (Figure 2B). These
data indicated an association between enhanced CCL2 expression
in Tgfbr2FspKO fibroblasts and recruitment of TAMs, leading to the
hypothesis that CCL2 derived from TGF-β signaling–deficient fibro-
blasts enhancesmammary tumor progression throughTAMrecruitment.
Antibody Neutralization of CCL2 Inhibits Mammary
Tumor Progression and TAM Recruitment
To determine the functional contribution of CCL2 derived from
Tgfbr2FspKO fibroblasts in mammary tumorigenesis, two approaches
were used to inhibit CCL2 activity. First, tumor-bearing mice were
Figure 3. Effect of CCL2 neutralization on primary tumor and recruitment of TAMs. (A) Peripheral blood samples were harvested from
tumor-bearing mice 4 and 24 hours after injection and analyzed for the presence of anti-CCL2 or control IgG by ELISA. (B) Primary tumor
mass of 4T1:Tgfbr2FspKO graft recombinants treated with saline vehicle control, rat IgG control, or anti-CCL2. Tumor (t) and kidney
(k) delineated by dotted line. (C) Primary tumor cell digests from each treatment group were analyzed for the presence of F4/80,
Cd11b-positive cells by flow cytometry. (D) Liver metastases were detected by stereomicroscopy of gross tissues and counted. Repre-
sentative lesions on liver tissues are outlined. Liver incidence is noted below micrographs. Graphs are represented by mean ± SEM.
Statistical analysis was performed by ANOVA with Bonferroni’s multiple comparison tests of all groups. Statistical significance was deter-
mined by P < .05 in comparison to rat IgG.
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treated with neutralizing antibodies to CCL2, which has been previ-
ously shown to inhibit CCL2-induced inflammation in mice [23,24].
Tgfbr2FspKO fibroblasts were cografted with 4T1 mammary carcinoma
cells in the subrenal capsule of nude mice. Seven days after treatment,
grafted mice were injected in the intraperitoneum with 5 mg/kg of anti-
CCL2, control IgG, or 0.9% saline vehicle control for an additional
14 days. To determine the stability of anti-CCL2 injected inmice, samples
of blood serum were collected from mice by tail vein and were analyzed
for levels of anti-CCL2 4 and 24 hours before the last injection. ELISA
of blood serum indicated significant levels of anti-CCL2 24 hours after
injection, although the levels were lower compared with the levels of
control rat IgG (Figure 3A). Compared with IgG controls, anti-CCL2
treatment resulted in a significant reduction in primary mammary tumor
mass (Figure 3B) associated with decreased TAM recruitment to the pri-
mary tumor (Figure 3C). In addition, anti-CCL2 treatment also signifi-
cantly decreased the number but not the incidence of liver metastases
compared with rat IgG- or saline-treated mice (Figure 3D). These data
indicate that systemic inhibition of CCL2 significantly inhibits tumor
growth and metastatic spread associated with TAM recruitment.
Immunohistochemistry analyses were performed on primary tumor
sections to determine the effects of anti-CCL2 treatment on tumor cell
proliferation and survival. Anti-CCL2–treated tumors exhibited sig-
nificant decreases in cellular proliferation as indicated by K67 staining
(Figure 4A) compared with IgG- and saline-treated mice. Whereas anti-
CCL2 treatment resulted in a significantly increased cleaved caspase-3
staining compared with saline-treated groups, there were no significant
differences in cleaved caspase-3 expression between IgG- and anti-CCL2–
treated groups because IgG-treated groups also exhibited increased
apoptosis compared with saline (Figure 4B). In summary, these data
indicate that the reduction in cellular proliferation and cell survival in
anti-CCL2–treatedmice was associated with an overall reduction in pri-
mary tumor growth and liver metastases.
siRNA Silencing of CCL2 in Tg fbr2FspKO Fibroblasts
Inhibits Liver Metastases but Does Not Significantly
Reduce TAM Recruitment
Studies have shown that other cell types in the tumor microenviron-
ment including macrophages, endothelial cells, and mammary epithelial
cells expressed CCL2 [25,26]. To determine the functional contribu-
tion of CCL2 derived from Tgfbr2 deficient fibroblasts, an siRNA
approach to target CCL2 expression was used. siRNA targeting two dif-
ferent regions of theCcl2 transcript were stably expressed in Tgfbr2FspKO
fibroblasts, resulting in the generation of two cell lines, one exhibiting
35% knockdown (3CCL2−) and the other exhibiting 82% knockdown
(1CCL2−) of CCL2 expression compared with control Tgfbr2FspKO
fibroblasts expressing siRNA to GFP (GFP−) (Figure 5A). Cografting
4T1 mammary carcinoma cells with fibroblast cell lines expressing vary-
ing levels of CCL2 allowed the determination of dose-dependent ef-
fects of CCL2 derived from mammary fibroblasts on mammary tumor
progression. Compared with cografting 4T1 cells with GFP− control
fibroblasts, cografting of 3CCL2− fibroblasts did not result in significant
changes to tumor mass (Figure 5B), TAM recruitment (Figure 5C), or
liver metastases (Figure 5D). These data indicate that a 35% knockdown
in CCL2 secretion in Tgfbr2FspKO fibroblasts was not sufficient to in-
hibit mammary tumor growth, TAM recruitment, or metastatic spread.
Cografting with 1CCL2− fibroblasts did not result in significant changes
to primary tumor growth (Figure 5B). We observed a small decrease in
TAM recruitment, which was not statistically significant (Figure 5C). In
addition, cografting with 1CCL2− fibroblasts resulted in a significant
decrease in the number but not in the incidence of liver metastases (Fig-
ure 5D). These data indicate that CCL2 derived fromTgfbr2FspKO fibro-
blasts does not significantly regulate primary tumor growth or TAM
recruitment but does, in part, regulate liver metastases of 4T1mammary
carcinoma cells, possibly in a concentration-dependent manner.
Immunohistochemistry analyses were performed to determine the ef-
fects of inhibiting CCL2 by knockdown in fibroblasts on primary tumor
cell proliferation and survival. Transplantation of 4T1 mammary carci-
noma cells with 3CCL2− fibroblasts did not result in significant changes
in Ki67 staining or cleaved caspase-3 staining (Figure 6, A and B). Co-
grafting of 4T1 carcinoma cells with 1CCL2− fibroblasts also did
not result in changes to Ki67 staining but did result in significantly
increased cleaved caspase-3 staining. These data indicate that CCL2
derived from Tgfbr2FspKO fibroblasts does not regulate tumor cell prolifer-
ation but does regulate tumor cell survival, possibly in a concentration-
dependent manner.
Discussion
Previous studies have shown that TGF-β signaling in fibroblasts sup-
presses mammary carcinoma cell growth, invasion, and metastatic spread
Figure 4. Effect of anti-CCL2 treatment on tumor cell proliferation
and apoptosis. Primary tumor graft recombinants were paraffin-
embedded, sectioned, and immunostained for the expression of
(A) Ki67 as a marker for cell proliferation and (B) cleaved caspase-3
as a marker for apoptosis. Statistical analysis was performed by
ANOVA with Bonferroni’s multiple comparison tests of all groups.
Statistical significancewas determined by P< .05. Scale bar, 40 μm.
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by regulating expression of soluble factors that mediate tyrosine receptor
kinase signaling inmammary carcinoma cells [8]. In these present studies,
the data collectively support that TGF-β signaling in mammary fibro-
blasts inhibits CCL2 chemokine expression to negatively regulate TAM
recruitment and tumor metastases. These studies reveal important in-
sight into the relationship between TGF-β and CCL2 signaling pathways
during breast cancer progression and reveal important roles for CCL2 in
regulating fibroblast interactions with mammary carcinoma cells and
other stromal cells in the mammary tumor microenvironment.
Whereas previous studies have demonstrated that CCL2 regulates
breast cancer progression throughTAMrecruitment, the effects of siRNA
knockdown in CCL2 in mammary fibroblasts presented here indicate
that CCL2 regulates breast cancer progression in part by mediating
fibroblast-carcinoma cell interactions. We observed that a 35% knock-
down in CCL2 expression in Tgfbr2FspKO fibroblasts was not sufficient
to inhibit macrophage recruitment, although a slight reduction in the
number of liver metastases was noted. An 82% knockdown in CCL2 ex-
pression resulted in a small but not statistically significant reduction in
macrophage recruitment but did significantly reduce liver metastases
and cell survival. The different effects of CCL2 knockdown in fibroblasts
on macrophage recruitment and 4T1 metastases indicate that CCL2 se-
creted fromTgfbr2FspKO fibroblasts acts directly onmammary carcinoma
cells to regulate cell survival and metastatic spread (Figure 7A). Interest-
ingly, a recent study demonstrated a different mechanism through which
CCL2 may regulate the metastatic spread. This particular study demon-
strated that overexpression of CCL2 in prostate cancer cells resulted in
increased bone metastases in mice, associated with increased osteoclast
formation, indicating thatCCL2may act directly or indirectly on stromal
cells of distal sites to regulate metastatic spread [16]. In summary, these
studies indicate that CCL2may regulate late-stage carcinoma progression
at the primary tumor site and in distal sites of metastasis, through com-
plex, multiple mechanisms.
Currently, the functional contribution of CCL2/CCR2 signaling
in cancer cells remains largely unclear. The polymorphism CCR264-l
has been associated with the development sporadic breast cancer
[27], and CCR2 overexpression significantly correlates with the devel-
opment of glioblastoma [28]. Studies of CCL2 signaling in the human
PC-3 prostate cancer cell line demonstrate that CCL2 promotes cell
survival through an AKT-independent mechanism, by negatively regu-
lating AMP-activated protein kinase resulting in mammalian target of
rapamycin complex activation and sustained expression of survivin [29].
In addition, current studies in our laboratory indicate that CCL2/
CCR2 signaling regulates mammary carcinoma cell survival and inva-
sion through a mitogen-activated protein kinase–dependent mechanism
(unpublished observations). These studies indicate that CCL2 promotes
cell survival in different cancer cell types, potentially through multi-
ple mechanisms. Further studies are underway in our laboratory to
further understand the molecular mechanisms through which CCL2
mediates stromal–breast cancer cell interactions.
An important association between TAM recruitment and CCL2 in
mammary tumor progression was also observed in these current studies.
Given that anti-CCL2 antibody inhibitedmammary tumor progression
Figure 5. Effect of siRNA knockdown in Tgfbr2FspKO fibroblasts on 4T1 tumor growth and recruitment of TAMs. (A) Conditioned medium
from parental fibroblasts (Par), fibroblasts stably expressing control siRNA (GFP−), or siRNA targeting CCL2 (3CCL2− and 1CCL2−) were
analyzed for the secretion of CCL2 by ELISA. (B) Primary tumors from mice grafted with 4T1 cells with Tgfbr2FspKO fibroblasts expressing
siRNA to control GFP or CCL2 were weighed 21 days after grafting. (C) Primary tumor cell digests from each experimental group were
analyzed for the presence of F4/80, Cd11b-positive cells by flow cytometry. (D) Metastatic surface lesions on the liver were detected by
stereomicroscopy and counted. The counts are represented as the number of lesions per mouse. The incidence of liver metastases is noted
below graph and is represented as the number ofmice exhibiting lesions/total number ofmice examined. Statistical analysis was performed
by ANOVA with Bonferroni’s multiple comparison tests of all groups. Statistical significance was determined by P < .05.
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more significantly than siRNA knockdown of CCL2 in mammary fi-
broblasts, it is possible that CCL2 derived from TAMs also promotes
primary tumor growth and TAM recruitment (Figure 7B). Anti-CCL2
treatment but not siRNA knockdown of CCL2 in fibroblasts inhibited
primary tumor growth, indicating that systemic inhibition of CCL2
expressed in other cell types may also contribute to mammary tumor
growth. Because recombinant CCL2 does not significantly affect cellu-
lar proliferation in vitro (data not shown), CCL2 may enhance primary
tumor growth, indirectly through enhancement of TAMs that have
been shown to express a number of growth factors [1,30]. This pos-
sibility is also supported in previous studies, in which anti-CCL2 treat-
ment of tumor-bearing mice inhibited growth and metastases of MCF7
and MDA-231 cells orthotopically grafted in severe combined immuno-
deficient mice along with a decrease in macrophage recruitment [17,31].
These studies further suggested that CCL2 expression was derived
from TAMs that were recruited to the primary tumor through a CCL2-
dependent positive feedback mechanism [31]. CCL2-dependent re-
cruitment of TAMs to the primary tumor has also been demonstrated
in a transplantation model of prostate cancer [16]. Anti-CCL2 treat-
ment of prostate tumor-bearing mice inhibited tumor growth associ-
ated with decreased macrophage recruitment, indicating that CCL2
may regulate tumor progression through a macrophage-dependent
mechanism in multiple tumor types. Because Tgfbr2FspKO fibroblasts
cografted with mammary carcinoma cells resulted in enhanced recruit-
ment of TAMs, it is possible that the TAM recruitment was initiated by
Tgfbr2FspKO fibroblasts, subsequently resulting in a CCL2-dependent
positive feedback mechanism to recruit additional TAMs over time.
The data presented here support an important association between
CCL2 and TAM recruitment in metastatic disease. Collectively, these
studies demonstrate multifunctional roles for CCL2 signaling in breast
cancer and indicate that targeting CCL2 in breast cancer would inhibit
both epithelial and mesenchymal cell types.
Studies presented here indicate that differing levels of CCL2 in the tu-
mor microenvironment significantly affect the activity of stromal cells
and mammary carcinoma cells. Cografting 4T1 cells with 1CCL2−
fibroblasts but not 3CCL2− fibroblasts significantly inhibited liver me-
tastases. In addition, cografting experiments with 1CCL2− fibroblasts
but not with 3CCL2− fibroblasts resulted in a small decrease in macro-
phage recruitment, indicating that local concentrations of CCL2 may
stimulate stromal cells at levels different from mammary carcinoma
cells. This notion is supported in previous studies that show that high
concentrations of CCL2 in mammary tumors desensitize and down-
regulate chemokine receptor signaling of T cells while supporting tumor
growth [32]. Although CCL2 has been found to bind and activate
CCR2 in mouse and human macrophages with kd values of 22.5 and
25.7 nM, respectively [33], this study, as well as previous studies [32],
indicates that CCL2/CCR2 binding kinetics differ among mammary
Figure 6. Effect of CCL2 knockdown in fibroblasts on tumor cell
proliferation and survival. Immunostaining of primary sections of con-
trol, 3CCL2−, and 1CCL2− cocultures for the expression of Ki67 as a
marker for cell proliferation (A) and of cleaved caspase-3 as a marker
for apoptosis (B). Statistical analysis was performed by ANOVA with
Bonferroni’s multiple comparison tests. Statistical significance was
determined by P < .05.
Figure 7. Model for the role of CCL2 signaling in the breast tumor
microenvironment. (A) Mammary fibroblasts increase CCL2 expres-
sion when TGF-β signaling is downregulated. The increased ex-
pression of CCL2 derived from mammary fibroblasts acts directly
on mammary carcinoma cells to enhance carcinoma survival and
invasion. (B) The expression of CCL2 in the breast cancer micro-
environment enhances mammary tumor growth, survival, and in-
vasion through a dual mechanism: directly stimulating mammary
carcinoma cells and recruitment of TAMs.
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epithelial cells or other mesenchymal cell types. Given that chemokine re-
ceptor desensitization and down-regulation is a common mechanism in
regulating G-coupled receptor signaling in multiple cell types [32,34,35],
it would be important in the future to clarify and understand the signal-
ing kinetics of CCL2 chemokine signaling among stromal cells and car-
cinoma cells to predict its biological effects on tumor progression.
This study of siRNA knockdown in CCL2 in fibroblasts demon-
strates a fibroblast-specific contribution of CCL2 signaling in regulating
mammary tumor progression. In addition, data presented here support
the potential effectiveness for targeting the CCL2/CCR2 network in
metastatic disease. However, given that CCL2 acts on multiple cell
types in the tumor microenvironment and that chemokine signaling
is dependent on ligand concentrations, it is important to clarify the mo-
lecular and cellular mechanisms of inflammatory chemokine signaling
in breast cancer to design an effective therapeutic regimen for the treat-
ment of metastatic disease.
Acknowledgments
The authors thankWei Bin Fang (University of Kansas Medical Center),
Karen Stunk (University of North Carolina, Chapel Hill), and Rebecca
Cook (Vanderbilt University, Nashville, TN) for the critical reading of
the manuscript. The authors also thank the Flow Cytometry Core Fa-
cility for assistance with the flow cytometry studies and the Biostatistical
Core Facility at the Kansas University Medical Center for assistance in
statistical analysis of data.
References
[1] Allavena P, Sica A, Solinas G, Porta C, and Mantovani A (2008). The inflamma-
tory micro-environment in tumor progression: the role of tumor-associated macro-
phages. Crit Rev Oncol Hematol 66, 1–9.
[2] Bierie B and Moses HL (2005). Under pressure: stromal fibroblasts change their
ways. Cell 123, 985–987.
[3] Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H, Chen H,
Omeroglu G, Meterissian S, Omeroglu A, et al. (2008). Stromal gene expression
predicts clinical outcome in breast cancer. Nat Med 14, 518–527.
[4] Bieche I, Lerebours F, Tozlu S, Espie M, Marty M, and Lidereau R (2004). Mo-
lecular profiling of inflammatory breast cancer: identification of a poor-prognosis
gene expression signature. Clin Cancer Res 10, 6789–6795.
[5] Abraham S, Sawaya BE, Safak M, Batuman O, Khalili K, and Amini S (2003).
Regulation of MCP-1 gene transcription by Smads and HIV-1 Tat in human glial
cells. Virology 309, 196–202.
[6] Akhurst RJ and Derynck R (2001). TGF-B signaling in cancer—a double edged
sword. Trends Cell Biol 11, S44–S50.
[7] Wells RG and Discher DE (2008). Matrix elasticity, cytoskeletal tension, and
TGF-β: the insoluble and soluble meet. Sci Signal 1, pe13.
[8] Cheng N, Bhowmick NA, Chytil A, Gorksa AE, Brown KA, Muraoka R,
Arteaga CL, Neilson EG, Hayward SW, and Moses HL (2005). Loss of TGF-β
type II receptor in fibroblasts promotes mammary carcinoma growth and invasion
through upregulation of TGF-α–, MSP- and HGF-mediated signaling networks.
Oncogene 24, 5053–5068.
[9] Cheng N, Chytil A, Shyr Y, Joly A, and Moses HL (2007). Enhanced hepatocyte
growth factor signaling by type II transforming growth factor-{beta} receptor knock-
out fibroblasts promotes mammary tumorigenesis. Cancer Res 67, 4869–4877.
[10] Boring L, Gosling J, Chensue SW, Kunkel SL, Farese RV Jr, Broxmeyer HE, and
Charo IF (1997). Impaired monocyte migration and reduced type 1 (TH1) cyto-
kine responses in C-C chemokine receptor 2 knockout mice. J Clin Invest 100,
2552–2561.
[11] Kurihara T, Warr G, Loy J, and Bravo R (1997). Defects in macrophage recruit-
ment and host defense in mice lacking the CCR2 chemokine receptor. J Exp Med
186, 1757–1762.
[12] Valkovic T, Lucin K, Krstulja M, Dobi-Babic R, and Jonjic N (1998). Expression
of monocyte chemotactic protein-1 in human invasive ductal breast cancer. Pathol
Res Pract 194, 335–340.
[13] Soria G, Yaal-Hahoshen N, Azenshtein E, Shina S, Leider-Trejo L, Ryvo L,
Cohen-Hillel E, Shtabsky A, Ehrlich M, Meshel T, et al. (2008). Concomitant
expression of the chemokines RANTES and MCP-1 in human breast cancer: a
basis for tumor-promoting interactions. Cytokine 44, 191–200.
[14] Lewis CE and Pollard JW (2006). Distinct role of macrophages in different tumor
microenvironments. Cancer Res 66, 605–612.
[15] Condeelis J and Pollard JW (2006). Macrophages: obligate partners for tumor cell
migration, invasion, and metastasis. Cell 124, 263–266.
[16] Mizutani K, Sud S, McGregor NA, Martinovski G, Rice BT, Craig MJ, Varsos ZS,
Roca H, and Pienta KJ (2009). The chemokine CCL2 increases prostate tumor
growth and bone metastasis through macrophage and osteoclast recruitment.
Neoplasia 11, 1235–1242.
[17] Lu X and Kang Y (2009). Chemokine (C-Cmotif) ligand 2 engages CCR2+ stromal
cells of monocytic origin to promote breast cancer metastasis to lung and bone. J Biol
Chem 284, 29087–29096.
[18] Brummelkamp TR, Bernards R, and Agami R (2002). A system for stable expres-
sion of short interfering RNAs in mammalian cells. Science 296, 550–553.
[19] Hayward S, Haughney PC, Rosen MA, Greulich KM, Weier HU, Dahiya R, and
Cunha GR (1998). Interactions between adult human prostatic epithelium and
rat urogenital sinus mesenchyme in a tissue recombination model. Differentiation
63, 131–140.
[20] Yang L, DeBusk LM, Fukuda K, Fingleton B, Green-Jarvis B, Shyr Y, Matrisian
LM, Carbone DP, and Lin PC (2004). Expansion of myeloid immune suppressor
Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis.
Cancer Cell 6, 409–421.
[21] Lu B, Rutledge BJ, Gu L, Fiorillo J, Lukacs NW, Kunkel SL, North R, Gerard C,
and Rollins BJ (1998). Abnormalities in monocyte recruitment and cytokine ex-
pression in monocyte chemoattractant protein 1–deficient mice. J Exp Med 187,
601–608.
[22] De Paepe B, Creus KK, and De Bleecker JL (2008). Chemokines in idiopathic
inflammatory myopathies. Front Biosci 13, 2548–2577.
[23] Brydon EW, Smith H, and Sweet C (2003). Influenza A virus–induced apoptosis
in bronchiolar epithelial (NCI-H292) cells limits pro-inflammatory cytokine re-
lease. J Gen Virol 84, 2389–2400.
[24] Christophi GP, Hudson CA, Panos M, Gruber RC, and Massa PT (2009). Modu-
lation of macrophage infiltration and inflammatory activity by the phosphatase
SHP-1 in virus-induced demyelinating disease. J Virol 83, 522–539.
[25] Salcedo R, Ponce ML, Young HA, Wasserman K, Ward JM, Kleinman HK,
Oppenheim JJ, and Murphy WJ (2000). Human endothelial cells express CCR2
and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progres-
sion. Blood 96, 34–40.
[26] Ueno T, Toi M, Saji H, Muta M, Bando H, Kuroi K, Koike M, Inadera H, and
Matsushima K (2000). Significance of macrophage chemoattractant protein-1 in
macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin
Cancer Res 6, 3282–3289.
[27] Zafiropoulos A, Crikas N, Passam AM, and Spandidos DA (2004). Significant
involvement of CCR2-64I and CXCL12-3a in the development of sporadic breast
cancer. J Med Genet 41, e59.
[28] Liang Y, Bollen AW, and Gupta N (2008). CC chemokine receptor-2A is fre-
quently overexpressed in glioblastoma. J Neurooncol 86, 153–163.
[29] Roca H, Varsos ZS, and Pienta KJ (2009). CCL2 is a negative regulator of AMP-
activated protein kinase to sustain mTOR complex-1 activation, survivin expression,
and cell survival in human prostate cancer PC3 cells. Neoplasia 11, 1309–1317.
[30] Porta C, Subhra Kumar B, Larghi P, Rubino L, Mancino A, and Sica A (2007).
Tumor promotion by tumor-associated macrophages. Adv Exp Med Biol 604,
67–86.
[31] Fujimoto H, Sangai T, Ishii G, Ikehara A, Nagashima T, Miyazaki M, and
Ochiai A (2009). Stromal MCP-1 in mammary tumors induces tumor-associated
macrophage infiltration and contributes to tumor progression. Int J Cancer 125,
1276–1284.
[32] Kurt RA, Baher A, Wisner KP, Tackitt S, and Urba WJ (2001). Chemokine
receptor desensitization in tumor-bearing mice. Cell Immunol 207, 81–88.
[33] Wang JM, Hishinuma A, Oppenheim JJ, and Matsushima K (1993). Studies of
binding and internalization of human recombinant monocyte chemotactic and
activating factor (MCAF) by monocytic cells. Cytokine 5, 264–275.
[34] Devalaraja MN and Richmond A (1999). Multiple chemotactic factors: fine
control or redundancy? Trends Pharmacol Sci 20, 151–156.
[35] Ozawa S, Kato Y, Komori R, Maehata Y, Kubota E, and Hata R (2006). BRAK/
CXCL14 expression suppresses tumor growth in vivo in human oral carcinoma
cells. Biochem Biophys Res Commun 348, 406–412.
Neoplasia Vol. 12, No. 5, 2010 CCL2 Regulates Stromal: Epithelial Interactions Hembruff et al. 433
